3 ms·
i'd argue (without evidence) that medical and biotech startups probably require more up front capital and longer lead times to see a possible return on investme
by shoo 7y ago
i'd argue (without evidence) that medical and biotech startups probably require more up front capital and longer lead times to see a possible return on investment vs e.g. yet another SaaS
so maybe this is working as intended
- danieltillett 7y agoI would argue with evidence (personal experience) that you would be right :)